Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double …

JT Merrill, DJ Wallace, M Petri, KA Kirou… - Annals of the …, 2011 - ard.bmj.com
Background Type I interferons (IFNs) appear to play a central role in disease pathogenesis
in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods …
被引用次数：255 相关文章

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double …

JT Merrill, DJ Wallace, M Petri, KA Kirou… - Annals of the …, 2011 - pure.psu.edu
Background: Type I interferons (IFNs) appear to play a central role in disease pathogenesis
in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods …

[引用][C] Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre …

JT MERRILL, DJ WALLACE, N OLSEN… - Annals of the …, 2011 - pascal-francis.inist.fr
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal
antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised …

[引用][C] Safety profile and clinical activity of sifalimumab, a fully human anti-interferon monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre …

JT Merrill, DJ Wallace, M Petri, KA Kirou… - Annals of the …, 2011 - cir.nii.ac.jp
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon monoclonal
antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study …

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double …

JT Merrill, DJ Wallace, M Petri, KA Kirou… - Annals of the …, 2011 - europepmc.org
Background Type I interferons (IFNs) appear to play a central role in disease pathogenesis
in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods …

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon [alpha] monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre …

JT Merrill, DJ Wallace, M Petri, KA Kirou… - Annals of the …, 2011 - search.proquest.com
Background Type I interferons (IFNs) appear to play a central role in disease pathogenesis
in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods …

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double …

JT Merrill, DJ Wallace, M Petri… - Annals of the …, 2011 - pure.johnshopkins.edu
Background: Type I interferons (IFNs) appear to play a central role in disease pathogenesis
in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods …

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double …

JT Merrill, DJ Wallace, M Petri, KA Kirou… - Annals of the …, 2011 - ard.bmj.com
Background Type I interferons (IFNs) appear to play a central role in disease pathogenesis
in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods …

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double …

JT Merrill, DJ Wallace, M Petri… - Annals of the …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Type I interferons (IFNs) appear to play a central role in disease pathogenesis
in systemic lupus erythematosus (SLE), making them potential therapeutic targets. Methods …